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SUCCESSFUL USE OF C1 ESTERASE INHIBITOR PROTEIN IN A PATIENT WITH HEREDITARY
ANGIONEUROTIC EDEMA REQUIRING CORONARY ARTERY BYPASS SURGERY
John M. Alvarez, FRACS, Clayton, Victoria, Australia 
Hereditary angioneurotic edema (HANE) is an inherited
deficiency of an inhibitor protein (C1INH) that inactivates the
activated first component (C1) of the classical complement
pathway. With deficiency of C1INH, there is an unimpeded
action of activated C1 producing a depletion of the comple-
ment proteins and concurrent accumulation of their break-
down products. The result can be a marked increase in vas-
cular permeability and a coagulopathy.1 HANE is
characterized by episodic attacks with reported mortality
rates of 15% to 33%; surgery is a recognized trigger.1 This
report is the first to document the use of C1INH concentrate
(C1INH Inhibitor TIM3, Baxter Healthcare Corp, Edwards
Division, Deerfield, Ill) with cardiopulmonary bypass (CPB).
Clinical summary. A 53-year-old white man (height 169
cm, weight 70 kg) with triple vessel disease, a left ventricu-
lar ejection fraction of 30%, and unstable angina was referred
for urgent coronary artery bypass grafting (CABG). A 20-
year history of HANE with episodic life-threatening facial
and limb edema had been successfully controlled for only the
previous 7 years with danazol (Danacrine, Sanofi Winthrop),
200 mg daily. Preoperatively, total (C1INH-1) and functional
(C1INH-F) serum C1INH concentrations were 0.11 mg/dL
(normal range 0.19-0.43 mg/dL) and 0.28 U/mL (normal
range 0.8-1.2 mg/dL), respectively (Figs 1A and 1B).
Sixty minutes before anesthetic induction, 1000 units of
intravenous C1INH was given. CABG was performed with
CPB, hypothermia to 32°C, and with antegrade and retro-
grade blood cardioplegia. The left internal thoracic artery was
grafted to the left anterior descending coronary artery, and 2
saphenous vein grafts were anastomosed to the circumflex
and right coronary arteries (aortic crossclamp time 31 min-
utes, CPB time 51 minutes).
The patient was extubated 8 hours after an uneventful oper-
ation. One hour before extubation, 1000 units of intravenous
C1INH was given to minimize the potential for laryngeal
edema from endotracheal intubation. No evidence of a bleed-
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ing diathesis or significant limb, face, or neck edema
occurred, and he was discharged to his home 6 days later.
Discussion. HANE is an autosomal dominant disease with
2 variants: 85% of patients have a deficiency of C1INH and
15% of patients have normal serum levels but functionally
inactive C1INH. The majority of patients do not require long-
term drug treatment. Androgen therapy, which increases
hepatic synthesis of C1INH, is recommended for frequent or
life-threatening attacks.1
Optimal perioperative management for HANE is unclear.
Continuation of and/or several days of increased androgen
before the operation, 2 units of fresh-frozen plasma 24
hours before the operation, and/or a short course of anti-
fibrinolytic therapy have been recommended.1,4 Ostensibly,
outcome will be determined by the interaction between the
magnitude of the stressor (surgery) and the serum level of
C1INH-I/F. Records of C1INH-I/F in reported cases are
scarce. Hence such recommendations must be viewed with
caution.3 Importantly, no effective therapy exists for acute
attacks.3
CPB is particularly challenging to these patients. First, the
hemodilution associated with CPB is known to reduce serum
C1INH levels by 30% to 50%.3 Second, complement activa-
tion occurs during CPB and with the administration of prota-
mine. Furthermore, a safe lower level of C1INH is un-
known.1,3 Therefore these patients may have uncontrolled
complement activation.
Only 3 case histories of patients with HANE requiring
CPB have been reported.2,3 One patient, a child with only
biochemical evidence of HANE, had successful closure of an
atrial septal defect.3 Haering and Comunale3 reported on a
71-year-old man receiving long-term stanozolol therapy who
had an uncomplicated CABG. The dose of stanozolol was
doubled for 5 days before the operation. This patient’s base-
line serum C1INH level was 0.11 mg/dL (75% of normal).
No increase in C1INH was evident after 5 days of increased
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Fig 1A. Total (C1INH-I) serum C1INH levels at the following measurement times: Preop, baseline; or 1415,
before heparinization; or 1500, before CPB; or 1510, +10 minutes of CPB; or 1520, +20 minutes of CPB; or
1530, +30 minutes of CPB; or 1540, +40 minutes of CPB; or 1600, after CPB; or 1620, after total protamine
dose; day 1, 0900, before extubation; day 1, 1030, +90 minutes after extubation; day 1, 1630, +7.5 hours after
extubation; day 1, 1930, +12.5 hours after extubation.
androgen therapy. During CPB, serum C1INH concentration
fell to a nadir of 0.6 mg/dL (38% of normal) after prota-
mine administration.
Bonser and coworkers2 reported on a 74-year-old patient
requiring CABG who was on a program of long-term dana-
zol therapy (200 mg daily) and received the drug until the
day of the operation. Disseminated coagulopathy with gen-
eralized systemic and pulmonary edema immediately after
CPB proved fatal. This patient’s baseline C1INH level was
0.6 mg/dL (38% of normal). Bonser and colleagues2
believed that a maintenance dose of androgen therapy was
inadequate and suggested that higher doses should be
administered for at least 1 week before the operation in the
expectation that C1INH levels can be increased to greater
than 50% of normal. They concluded that CPB in patients
with C1INH deficiency is extremely hazardous. Neither
Bonser’s group2 nor Haering and Comunale3 measured
serum C1INH-F.
Our patient continued to receive androgen therapy until the
time of the operation. We have demonstrated that 1000 plas-
ma units of C1INH maintained the level of C11NH during
CPB. There was no significant reduction in either total or
functionally active serum C1INH (Figs 1A and 1B) during 60
minutes of CPB. The further administration of 1000 units of
C1INH before extubation doubled and maintained the serum
C1INH-I/F for 48 hours. The half-life of C1INH is 18 hours
(product information, Baxter Edwards Laboratories).
Therefore, depending on the baseline level, CPB can
reduce the serum C1INH concentration, with fatal conse-
quences. Hence measurement of preoperative serum C1INH-
I/F is important. In conclusion, the prophylactic use of
C1INH concentrate in patients with HANE requiring CPB
prevents serum C1INH-I/F levels from decreasing. Un-
controlled complement activation is prevented and potential-
ly fatal complications are thereby avoided. Given that a safe
lower limit of C1INH is not known and conventional therapy
for acute attacks is ineffective, the prophylactic use of C1INH
concentrate is recommended.
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Fig 1B. Functional C1INH-F serum C1INH levels. For legend, see Fig 1A. 
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